{"entity":{"id":"nct05853575","kind":"trial","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","aka":[],"tldr":"A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","summary":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05853575","url":"https://clinicaltrials.gov/study/NCT05853575"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["adagrasib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05853575","phase":"2","setting":"A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"Mirati Therapeutics Inc.","enrolled":200,"outcomes":[]},"route":"/trials/nct05853575/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}